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1.INTRODUCTION 
Oral drug delivery is the most desirable and preferred method of administering 
therapeutic agents for their systemic effects. In addition, the oral medication is generally 
considered as the first avenue investigated in the discovery and development of new drug 
entities and pharmaceutical formulations, mainly because of patient acceptance, 
convenience in administration, and cost-effective manufacturing process. For many drug 
substances, conventional immediate-release formulations provide clinically effective 
therapy while maintaining the required balance of pharmacokinetic and 
pharmacodynamic profiles with an acceptable level of safety to the patient. .( A Gupta 
et.al.,2010) 
Based on the desired therapeutic objectives, oral DDS may be assorted into three 
categories:  
• Immediate-release preparations,  
• Controlled-release preparations and 
• Targeted- release preparations.  
Immediate-Releasae Prepartions 
These preparations are primarily intended to achieve faster onset of action for 
drugs such as analgesics, antipyretics, and coronary vasodilators. Other advantages 
include enhanced oral bioavailability through transmucosal delivery and pregastric 
absorption, convenience in drug administration to dysphasic patients, especially the 
elderly and bedridden, and new business opportunities. 
Conventional IR formulations include fast disintegrating tablets and granules that use 
effervescent mixtures, such as sodium carbonate (or sodium bicarbonate) and citric acid 
(or tartaric acid), and superdisintegrants, such as sodium starch glycolate, crosscarmellose 
sodium, and crospovidone. Current technologies in fast-dispersing dosage forms include 
modified tableting systems, floss or Shear form technology, which employs application of 
centrifugal force and controlled temperature, and freeze-drying. (Y.H. Lee et.al, 2000) 
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Advantages of Immediate Release Drug Delivery  
System  
An immediate release pharmaceutical preparation offers:  
1. Improved compliance/added convenience  
2. Improved stability  
3. Suitable for controlled/sustained release actives  
4. Allows high drug loading.  
5. Ability to provide advantages of liquid medication in the form of solid preparation.  
6. Adaptable to existing processing and packaging machinery  
7. Cost- effective(Reddy.L.H et al.,2002) 
 
Desired Criteria for Immediate Release Drug Delivery System  
An immediate release dosage form should dissolve or disintegrate in the stomach within a 
short period.  
1. In the case of liquid dosage form it should be compatible with taste masking.  
2. Be portable without fragility concern.  
3. Have a pleasing mouth feel.  
4. It should not leave minimal or no residue in the mouth after oral administration.  
5. Exhibit low sensivity to environmental condition as humidity and temperature.  
6. Be manufactured using conventional processing and packaging equipment at low cost.  
7. Rapid dissolution and absorption of drug, which may produce rapid onset of action.      
( A Gupta et.al.,2010) 
 
EXCIPIENTS 
Excipients balance the properties of the actives in Immediate release dosage 
forms. This demands a thorough understanding of the chemistry of these excipients to 
prevent interaction with the actives. Determining the cost of these ingredients is another 
issue that needs to be addressed by formulators. The role of excipients is important in the 
formulation of fast-melting tablets. These inactive food-grade ingredients, when 
incorporated in the formulation, impart the desired organoleptic properties and product 
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efficacy. Excipients are general and can be used for a broad range of actives, except some 
actives that require masking agents.  
 
BULKING MATERIALS 
Bulking materials are significant in the formulation of fast-melting tablets. The 
material contributes functions of a diluent, filler and cost reducer. Bulking agents  
improve the textural characteristics that in turn enhance the disintegration in the mouth, 
besides; adding bulk also reduces the concentration of the active in the composition. The 
recommended bulking agents for this delivery system should be more sugar-based such as 
mannitol, polydextrose, lactitol, DCL (direct compressible lactose) and starch 
hydrolystate for higher aqueous solubility and good sensory perception. Mannitol in 
particular has high aqueous solubility and good sensory perception. Bulking agents are 
added in the range of 10 percent to about 90 percent by weight of the final composition. 
 
EMULSIFYING AGENTS:  
Emulsifying agents are important excipients for formulating immediate release 
tablets they aid in rapid disintegration and drug release. In addition, incorporating 
emulsifying agents is useful in stabilizing the immiscible blends and enhancing 
bioavailability. A wide range of emulsifiers is recommended for fast-tablet formulation, 
including alkyl sulfates, propylene glycol esters, lecithin, sucrose esters and others. These 
agents can be incorporated in the range of 0.05 percent to about 15 percent by weight of 
the final composition. 
  
LUBRICANTS 
Lubricants, though not essential excipients, can further assist in making these 
tablets more palatable after they disintegrate in the mouth. Lubricants remove grittiness 
and assist in the drug transport mechanism from the mouth down into the stomach. 
 
SUPER DISINTEGRANTS  
A disintegrant is an excipient, which is added to a tablet or capsule blend to aid in 
the break up of the compacted mass when it is put into a fluid environment. .( A Gupta 
et.al.,2010) 
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ADVANTAGES:  
1. Effective in lower concentrations  
2. Less effect on compressibility and flowability  
3. More effective intragranularly  
Some super disintegrants are 
• Sodium Starch Glycolate  used in concentration of 2-8 % & optimum is 4%.  
Mechanism of Action Rapid and extensive swelling with minimal gelling. 
Microcrystalline cellulose (Synonym: Avicel, celex) used in concentration of 2-15% of 
tablet weight. And Water wicking. 
 
• Cross-linked Povidone (crospovidone) (Kollidone) used in concentration of 2-5% 
of weight of tablet. Completely insoluble in water.  
Mechanism of Action Water wicking, swelling and possibly some deformation recovery. 
Rapidly disperses and swells in water, but does not gel even after prolonged exposure. 
Greatest rate of swelling compared to other disintegrants. Greater surface area to volume 
ratio than other disintegrants.  
 
• Low-substituted Hydroxyl Propyl Cellulose, which is insoluble in water. Rapidly 
swells in water. Grades LH-11 and LH-21 exhibit the greatest degree of swelling. 
Certain grades can also provide some binding properties while retaining 
disintegration capacity. Recommended concentration 1-5% . 
 
• Cross-linked Carboxy Methyl Cellulose Sodium ( Croscarmellose Sodium 
Mechanism of Action Wicking due to fibrous structure, swelling with minimal gelling. 
Effective Concentrations: 1-3% Direct Compression, 2-4% Wet Granulation. 
 
Gas Producing Disintegrants  
Gas producing disintegrants are used especially where extra rapid disintegration or 
readily soluble formulation is required. They have also been found of value when poor 
disintegration characteristics have resisted other methods of improvement. Care should be 
taken during tab letting, particularly on moisture level. Composition is based upon the 
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same principles as those used for effervescent tablets, the most common being mixtures 
of citric & tartaric acids plus carbonates or bicarbonates.  
In many instances lower concentration can be used with gas producing 
disintegrants than are required by other disintegrating agents. Certain peroxides that  
release oxygen have been tried, but they do not perform as well as those releasing carbon 
dioxide. 
 
 Controlled-Release Preparations 
The currently employed CR technologies for oral drug delivery are diffusion-
controlled systems; solvent activated systems, and chemically controlled systems. 
Diffusion-controlled systems include monolithic and reservoir devices in which diffusion 
of the drug is the rate-limiting step, respectively, through a polymer matrix or a polymeric 
membrane. Solvent-activated systems may be either osmotically controlled or controlled 
by polymer swelling. Chemically controlled systems release drugs via polymeric 
degradation (surface or bulk matrix erosion) or cleavage of drug from a polymer chain. It 
is worth mentioning here that the so-called programmed-release (‘‘tailored-release’’) 
profile of a final CR product is rarely the outcome of a single pharmaceutical principle. 
Depending on the specific physicochemical properties of the drug in question and desired 
therapeutic objectives, different formulation and CR principles may be proportionally 
combined within the same dosage form. This task appears to be simpler when realized in 
terms of appropriate selection of polymers and excipients that incorporate desired 
principles.( S.J. Wu et.al,1999)  
 
 Targeted-Release Preparations 
Site-specific oral drug delivery requires spatial placement of a drug delivery 
device at a desired site within the GI tract. Although it is virtually possible to localize a 
device within each part of GI tract, the attainment of site-specific delivery in the oral 
cavity and the rectum is relatively easier than in the stomach and the small and large 
intestines. The latter requires consideration of both longitudinal and transverse aspects of 
GI constraints. Some of the potential CR and site-specific DDSs will be 
described.(Jennifer Sudimack et.al,2000) 
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1.1 Types of Tablets 
With advancement in technology and increase in awareness towards modification 
in standard tablet to achieve better acceptability as well as bioavailability, newer and 
more efficient tablet dosage forms are being developed. 
 
FIGURE NO: 1 TYPES OF TABLETS 
TYPES OF TABLETS 
ORAL TABLETS 
FOR INGESTION TABLETS USED IN 
THE ORAL CAVITY 
TABLETS 
ADMINISTERED BY 
OTHERROUTES 
TABLETS USED TO 
PREPARE SOLUTION 
Standard compressed Tablets  
 
Modified Release Tablet 
Delayed action Tablet 
Multiple  Compressed Tablets 
Compression 
CoatedTablet 
LayeredTablet 
Inlay Tablet 
Lozenges and 
Troches 
SublingualT
ablet 
BuccalTablet 
 Dental Cones 
Vaginal Tablet 
Implants 
Effervescent 
Tablet 
Hypodermic Tablet 
Soluble Tablet 
Targeted Tablet 
Chewable Tablet 
Dispersible Tablet 
Mouth dissolved 
Tablet 
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1.1.1 Oral tablets for Ingestion 
These tablets are meant to be swallowed intact along with a sufficient quantity of 
potable water. Exception is chewable tablet. Over 90% of the tablets manufactured today 
are ingested orally. This shows that this class of formulation is the most popular 
worldwide and the major attention of the researcher is towards this direction. (Lachman 
L et.al,) 
 
1.1.1.1 Multiple Compressed Tablets 
The tablets in this category are prepared for two reasons: to separate physically or 
chemically incompatible ingredients and to produce repeat action/ prolonged action 
tablet. 
The tablet manufacturing machine is generally operated at relatively lower speed than for 
standard compression tablet. There are three categories under this class: 
I.  Multilayered tablets – two to three component systems. 
II. Compression coated tablets – tablet within a tablet. 
III. Inlay tablet – coat partially surrounding the core. 
The layered tablet is preferred over compression coated tablet as the surface contact is 
less and the production is simple and more rapid. 
 
I. Multilayered Tablets 
When two or more active pharmaceutical ingredients are needed to be 
administered simultaneously and they are incompatible, the best option for the 
formulation pharmacist would be to formulate multilayered tablet. It consists of several 
different granulations that are compressed to form a single tablet composed of two or 
more layers and usually each layer is of different colour to produce a distinctive looking 
tablet. Each layer is fed from separate feed compression to avoid contamination. 
Therefore, each layer undergoes light compression as each component is laid down. This 
avoids granules intermixing if the machine vibrates. For example, admixture containing 
PhenylephedrinHCL and Ascorbic Acid with Paracetamol. 
Paracetamol + phenylephedrine Hydrochloride → one layer 
Paracetamol + ascorbic acid →  another layer. 
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Figure No:2 Multilayered Tablet 
 
II. Compression Coated Tablets 
This type of tablet has two parts, internal core and surrounding coat. Thecore is 
small porous tablet and prepared on one turret. For preparing finaltablet, a biggerdie 
cavity in another turret is used in which first the coatmaterial is filled to half and then 
core tablet is mechanically transferred,again the remaining space is filled with coat 
material and finally compressionforce is applied. This tablet readily lend itself in to a 
repeat action tablet as the outer layer provides the initial dose while the inner core release 
the drug later on. But, when the core quickly releases the drug, entirely different blood 
level is achieved with the risk of over dose toxicity. To avoid immediate release of both 
the layers, the core tablet is coated with enteric polymer sothat it will not release the drug 
in stomach while, the first dose is addedin outer sugar coating. Even so, coating operation 
requires interpretation while manufacturing and dawdling the manufacturing process. 
Sometimes, inner coremay be of liquid formulation to provide immediate release of core 
after the coat gets dissolved. . (Rawlins EA editor, 1995). 
 
 
 
Figure No:3 Compression Coated Tablet 
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III. Inlay tablets 
A type of layered tablet in which instead the core tablet being completely 
surrounded by coating, top surface is completely exposed. While preparation, only the 
bottom of the die cavity is filled with coating material and core is placed upon it. When 
compression force is applied, some coating material is displaced to form the sides and 
compress the whole tablet. It has some advantages over compression coated tablets: 
i) Less coating material is required. 
ii) Core is visible so coreless tablets can be easily detected. 
iii) Reduction in coating forms a thinner tablet and thus freedom from cappingof top 
coating. 
 
 
     Figure No:4 Inlay Tablets 
 
1.1.1.2 Standard compressed tablets 
These are the standard uncoated tablets made by either direct compressionor wet 
granulation or dry granulation or double compaction. 
    
 
Figure No:5 Standard Compressed Tablet 
They may be used for local action in gastro-intestinal tract or systemic action. 
When the tablet exert local action, they are formulated as more water insoluble by means 
of selecting slow dissolving excipients and thus provides local action for long time 
period.  e.g., antacids and adsorbents. The drugs that produce systemic action have some 
aqueous solubility and designed to disintegrate and dissolve quickly so that the drug can 
be quickly absorbed and produce systemicaction. Generally, an API exhibits 
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bioavailability depending upon Biopharmaceutical Class, which is based on water 
solubility and gastro-intestinal membrane permeability criteria. But, it can be altered by 
appropriate selection of excipients and processing technology. 
 
1.1.1.3 Modified Release tablets 
The main aim behind formulation of this dosage form is to release the medicament 
Slowly for long time duration after administration of a single tablet. 
 
 
Figure No:6 Graphical Comparison of Blood Concentration Vs Time 
A widespread use of this type of tablet is seen in present scenario, as well as many 
researchers have concentrated their attention in this direction. This is mainly because of 
improvement in patient’s compliance as the dosage frequency is reduced, patient can take 
an undisturbed sleep at night, it’s also beneficial for psychiatric patients who forget to 
take their tablets regularly and thedose related side effects and toxicities are reduced. Any 
adjuvant that can water uptake rate, swelling and gelling characteristics of Matrixing 
agents can alter the release rate of API e.g., electrolytes in HPMC matrix tablet.  It’s also 
possible to achieve pulsed drug release. Weakly basic drugs exhibit good solubility at low 
pH while less soluble at high pH conditions, which can result in incomplete drug release 
for sustained release formulations. The drug release can be modified by providing 
suitable micro environmental pH in the tablet e.g., acidic polymer, succinic acid, etc. 
Similarly, inclusion of alkaline polymers results in desirable drug release of acidic drugs. 
On the other hand, formulation of this type of dosage form presents challenge for the 
formulator increases the cost of manufacturing, chances of burst drug release and drop in 
drug release rate in terminal phase and thus incomplete release on API. In case of 
accidental poisoning, the doctor has to deal with special treatment problems. Due to large 
Introduction 
size, patient may feel difficulties in swallowing as the matrixing agent to drug ratio is 
high. Classic approaches are usually based on adaptation of either film coated or multi 
particulate technologies or those involving slow release matrices. (Lachman L et. al) 
 
Coating technology 
It combines semi permeable coatings and osmotic tablet cores to produce “zero 
order release” technology. Attention is also focused to trigger drug releaseat critical time 
point e.g., to achieve drug release 1-2 hours before the patient awakens. Alza’s prolific 
research activities have yielded a technology called “Ringcap” which is based on a tablet, 
preferentially film coated, partially coated with a series of rings whose respective 
thickness provides the means of moderating the rate at which the drug is released from 
final dosage form. 
         
 
 
Figure No:7 Ringcap (Coated) Tablet 
 
Matrix technology 
 Matrix products exhibit first order (or perhaps square-root-of-time)drug release 
characteristics. In order to achieve zero order release characteristics, it’s necessary to 
employ specially designed materials or strategies that seekto manipulate tablet structure 
or geometry. Combination of conventional HPMC matrix technology with upper and 
lower layer. This helps to moderate drug release by increase in surface area with 
concomitant reduction in drug concentration within the device. 
 
    Figure No:8 Matrix Tablet 
 
  core 
  coat 
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Releases of medicament can follow various mechanisms (2) 
i) Diffusion is rate limiting 
Diffusion is driving force where the movement of drug molecules occurs from 
high concentration in the tablet to lower concentration in gastro intestinal fluids. This 
movement depends on surface area exposed to gastric fluid, diffusion pathway, drug 
concentration gradient and diffusion coefficient of the system. 
 
 
Figure No:9 Diffusion Release Pattern 
In practice, we can follow either of the two methods, 
1. The drug is formulated in an insoluble matrix; the gastric fluid penetrates the dosage 
form and dissolves the medicament and release the drug through diffusion. 
2. The drug particles are coated with polymer of defined thickness so as the portion of 
drug slowly diffuse through the polymer to maintain constant drug level in blood. 
 
ii) Dissolution is rate limiting 
The drugs with poor water solubility (BCS class 2 and4) are inherently sustained 
release forms. While for water soluble drugs, it’s possible to incorporate a water insoluble 
carrier to reduce dissolution of the drug particles are coated with this type of materials  
E.g. Polyethylene Glycol. One may skip the use of disintegrating agent to promote 
delayed release. (Lachman L et.al) 
 
iii) Osmotic pressure is rate limiting 
Osmosis is a phenomenon in which the flow of liquid occurs from lower 
concentration to higher concentration through a semi permeable membrane which allows 
transfer of liquid only. The whole drug is coated with a semi permeable membrane with a 
hole on one end of tablet made by a laser beam. The gastric fluid penetrates through the 
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membrane, solubilizes the drug and increases the internal pressure which pumps the drug 
solution out of the aperture and releases the drug in gastric environment. The delivery rate 
is constant provided that the excess of drug present inside the tablet. But, it declines to 
zero once the concentration drops below saturation. 
 
 
              
Figure No:10 Osmotic Release Pattern 
 
iv) Release is controlled by ion exchange 
Ion exchangers are water insoluble resinous materials containing salt forming 
anionic or cationic groups. While manufacturing, the drug solution is mixed with resin 
and dried to form beads which are tableted. The drug release depends upon high 
concentration of charged ions in gastrointestinal tract where, the drug molecules are 
exchanged and diffused out of the resin into the surrounding fluid. This mechanism relies 
upon the ionic environment of resin and not pH or enzyme on absorption site.(Aulton M.) 
 
1.1.1.4 Delayed action tablets 
Enteric coated tablet is such an example of delayed action tablet. This formulation 
is preferred when, 
i) The API irritates gastric mucosa e.g., aspirin or strong electrolytes 
ii) Drugs that produce nausea and vomiting. 
iii) API is sensitive to low pH e.g., erythromycin 
iv) When it’s necessary to release the drug undiluted. e.g., intestinal antibacterial, 
antiseptic agents, intestinal vermifuge, etc. 
The commonly used coating agents are: Cellulose acetate phthalate, Hydroxy methyl 
propyl phthalate, polyvinyl acetatephthalate, Eudragit®, etc. This dosage form is intended 
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to hydrateand begin to dissolve in duodenum (pH 4 to 6) or in small intestine where pH 
increases to 7 to 8. The presence of esterases or bile salts like surface active agents plays 
a role in drug release. (AultonM) 
 
1.1.1.5 Targeted tablets: 
When we need to release the API at a specific site in the elementary tract, targeted 
drug delivery is a preferred option. Depending upon the composition and release 
mechanism of a tablet, the drug is delivered to a particular region. Under this category, 
we have two types of tablet 
 
I. Gastro retentive Tablet 
This type of dosage form is to be opted when API release is desired in stomach 
(Antacids, API used against H.pylori infection)or site of absorption is either stomach or 
upper part of small intestine. 
 
 
Figure No:11 Floating Tablet 
Retain the drug for longer time period in stomach,following approaches can be used: 
i) Low density tablet (effervescent or non-effervescent) 
ii) Tablets that can expand in gastric environment (swelling or by unfolding) and thus 
increasing the size so that itcannot cross the pyloric sphincter. 
iii) Using muco-adhesive polymers that stick to mucosa of stomach and provide slow 
drug release. 
Supine position is to be avoided and also high level of fluid is necessary or if the 
swelling formulation leaves stomach before it swells it’s ineffective. Drugs like 
Diazepam, Levodopa, Benserazide, and Ciprofloxacin are successfully marketed in this 
formulation. 
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II. Colonic tablets 
When the aim is to deliver the drug into colon without dilution in other regions of 
gastrointestinal tract or the drug has poor absorption in stomach or small intestine, colonic 
drug delivery is an answer of choice. The pH in this region varies from 6.4 - 7 and 
presence ofmicrobial flora plays as important role in drug release especially in this region. 
Various mechanisms are adopted for drug release in this area are coating with pH 
sensitive polymer e.g., Eudragit®S100, Eudragit® L100, biodegradable polymer like 
polymers which are sensitive to colonic bacteria,bioadhesive polymers which selectively 
sticks to colonic mucosa e.g.,polycarbophils or polyethans, redox sensitive polymers that 
respond to redoxpotential in colon which expresses the total metabolic and bacterial 
action. 
 
1.1.1.6 Chewable tablets 
The patients who have difficulty in swallowing tablets whole or for children who 
have not yet learnt to swallow a tablet chewable tablet serves as an attractive alternative. 
The added advantage ofthis medication is that it can be taken at any time or when water is 
not available. Mannitol is normally used as a base due to low hygroscopic and more 
importantly,it gives pleasant, cooling sensation. Antacid tablets are invariably prepared as 
chewable to obtain quick ingestion relief as well as the antacid dose is toolarge to 
swallow and the activity is related to particle size. Another exampleis multivitamin tablet 
which a patient can take as a daily dose. (Lachman L et.al) 
 
1.1.1.7 Dispersible tablet 
These tablets disintegrate either rapidly in water,to form a stabilized suspension, 
or disperse instantaneously in the mouth to be swallowed without the aid of water. So, it’s 
preferred for pediatric patientswho cannot swallow a solid dosage form and the API is 
unstable if formulated inliquid formulation. Also helpful for patients having prolonged 
illness who are prone to nauseatic sensations if they have to swallow a tablet. The added 
advantage of this formulation is faster onset of action as compared to standard 
compressed tablet. The properties of the water dispersible tablet, such as 
porosity,hardness, disintegration time have necessary to investigate during manufacturing 
which decides the product performance. The common examples of API formulated in this 
dosage form are analgesics e.g., aspirin, ibuprofen, etc. 
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1.1.2 Tablets used in the oral cavity 
The tablets under this group are aimed release API inoral cavity or to provide 
local action in this region. The tablets under this category avoids first-pass metabolism, 
decomposition in gastric environment, nauseatic sensations and gives rapid onset of 
action. The tablets formulated for this region are designed to fit in proper region of oral 
cavity. 
 
1.1.2.1 Lozenges and troches 
The tablet is a flat faced at least about 18mm in diameter and meant to suck and 
dissolves in the mouth. The compressed tablet is called troches and the tablets produced 
by fusion or candy molding process are called lozenges. Flavours and sweeteners are 
added to make tablets palatable. The tablet generally contains sucrose or lactose and 
gelatin solution to impart smooth taste. Lozenges for local action in mouth/ throat are: 
antiseptics, antibiotics, demulcents, antitussive agents or astringents. To produce systemic 
action: multivitamin tablet. (AultonM) 
 
1.1.2.2 Sublingual tablets 
They are to be placed under the tongue and produce immediate systemic effect by 
enabling the drug absorbed directly through mucosal lining of the mouth beneath the 
tongue. 
 
     
      Figure no:12Sublingual Tablets 
The drug absorbed from stomach goes to mesenteric circulation which connects to 
stomach via portal vein. Thus, absorption through oral cavity avoids first-pass 
metabolism. The tablets are usually small and flat, compressed lightly to keep them soft. 
The tablet must dissolve quickly allowing the API to be absorbed quickly. It’s designed to 
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dissolve in small quantity of saliva. After the tablet is placed in the mouth below the 
tongue, the patient should avoid eating, drinking, smoking and possibly talking in order to 
keep the tablet in place. Swallowing of saliva should also be avoided since the saliva may 
contain dissolved drug. Bland excipients are used to avoid salivary stimulation. Due to 
inconvenience in administration, this dosage form is prepared only for those API(s) for 
which the only satisfactory nonparenteral method is this route. For example,  
Glyceryltrinitrate (vasodilator) and Isoprinosinesulphate (bronchodilator). (AultonM) 
 
1.1.2.3 Buccal tablets 
Completeness of drug absorption is desired but fast drug absorption is not 
intended. The tablets are designed not to disintegrate. They are flat elliptical or capsule 
shaped tablets as it can be easily held between gum and cheek. It’s placed near the 
opening of parotid duct to provide the medium to dissolve the tablet. 
 
 
                
Figure no:13 Buccal Tablets 
Since this tablet is to be kept for 30-60 minutes inoral cavity, care should be taken 
to see that all the ingredients are finely divided to avoid gritty or irritating sensation. This 
tablet is most often usedwhen replacement hormonal therapy is to be administered. 
Antifungal drugs are preferred to be administered by this route. e.g., Miconazole – under 
Clinical trial – still not available in market. 
 
1.1.2.4 Dental cones 
 These tables are designed to be loosely packed in theempty socket remaining 
following a tooth extraction. Main purpose behind the use of this tablet is either to 
prevent multiplication of bacteria in the socket by employing a slow releasing 
antibacterial compound or to reduce bleeding by an astringent or coagulant containing 
tablet. 
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     Figure no:14 Dental Cones 
It’s formulated to dissolve or erode slowly inpresence of a small volume of serum or fluid 
over 20-40 minutes period. 
 
1.1.2.5 Mouth Dissolved tablets/ Rapidly Dissolving tablets  
Known to the FDA as orally disintegrating tablets, they are also called mouth-
dissolving, fast-dissolving, rapid-melt, porous, or dispersible, quick dissolving. These 
kinds of tablets are preferred when fast action or relief is desired. Most commonly used 
drugs under this formulation are the agents active against Migraine. The tablets are 
designed to disintegrate as well as dissolve within one minute or some within 10 seconds 
of oral administration in limited quantity of saliva. They liquefy on tongue and patient 
swallows the liquid, without the need of water. A number of techniques are used to 
prepare these tablets, including lyophilization, soft direct compression. Matrices having 
an API and high porosity are also being prepared using sublimation process. Urea, 
urethane, ammonium carbonate, ammoniumbicarbonate, hexamethylene, benzoic acid, 
naphthalene and camphor are commonly used for sublimation processing as they volatize 
rapidly. After removal by sublimation, these inert volatile substances leave the matrices 
with a high porosity. Disintegrants and sugar based excipients, such as sodium 
starchglycolate, cross carmellose sodium, mannitol, xylitol, dextrose, fructose, maltose 
and poly dextrose have been incorporated in almost all the orally disintegrating dosage 
forms (ODDFs). Loading of drug is made by preparing a blank and drug is post loaded. 
Generally the drug in solution is added after which the solvent evaporates. Taste masking 
poses numerous challenges since the drug product dissolves in mouth, any taste of drug 
must be covered, either by flavoring technique or by micro encapsulation or nano 
encapsulation. A major drawback of most of these systems is that the packaging system 
needs a higher degree of protection due to the lower hardness and more friability of the 
porous nature of tablets, except the DuraSolv technology of CIMA Labs, which are 
suitable for rigors of bulk bottle packaging. Keep the orally disintegrating tablet in the 
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blister pack inside the outer foil pouch until the patient is ready to take the medicine. 
Make sure that operator’s hands are dry and peel opens the blister to remove the tablet. 
Place the tablet on tongue and let it dissolve. These dosage forms have become a delivery 
system of choice for most patients as they provide comfort for administration through out 
the day. Pharmaceutical companies, on the other hand, benefit from value addition in 
terms of product life-cycle management in today’s market. (AultonM) 
 
1.1.3 Tablets administered by other routes 
These tablets are administered by other route except for the oral cavity and so the 
drugs are avoided from passing through gastrointestinal tract. These tablets may be 
inserted into other body cavities ordirectly placed below the skin to be absorbed into 
systemic circulation from the site of application. 
 
1.1.3.1 Vaginal tablets 
This tablet undergoes slow dissolution and drug release in vaginal cavity of 
women. The shape is kept ovoid or pear shaped to facilitate retention in vagina. The tablet 
should be made compatible with plastic tube inserters who are designed to place the tablet 
in the upper region of vaginal tract. These tablets generally release antibacterial, 
antiseptics or astringents to treat vaginal infections or release steroids for systemic 
absorption. 
 
1.1.3.2 Implants 
These tablets are inserted into subcutaneous tissue by surgical procedures where 
they are very slowly absorbed over a period of a month or a year. A special injector with 
a hollow needle and plunger is used to administer the rod shaped tablet for other shapes, 
surgery is required. The tablets may be pellet, cylindrical or rosette shaped with diameter 
not more than 8mm. They are sterile formulation without excipients and made hard with 
large particle size to achieve gradual drug release. The tablets are produced by a sterile 
single punch hand operated machine in which the die cavity is filled with hand since the 
material does not normally flow well. Mainly, these tablets are prepared to deliver growth 
hormones to food producing animals and ear is the preferred site for administration of the 
drug. 
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1.1.4 Tablets used to prepare solution 
The tablets under this category are required to be dissolved first in water or other 
solvents before administration or application. This solution may be for ingestion or 
parenteral application or for topical use depending upon type of medicament used. 
 
1.1.4.1 Effervescent tablets 
The oral dosage forms are the most popular way of taking medication despite 
having some disadvantages like slow absorption and thus onset of action is prolong. This 
can be overcome by administrating the drug in liquid from but, many APIs have limited 
level of stability in liquid form. So, effervescent tablets acts as an alternative dosage 
form. The tablet 
is added into a glass of water just before administration and the drug solution or 
dispersion is to be drunk immediately. The tablet is quickly broken apart by internal 
liberation of CO2 in water due to interaction between tartaric acid and citric acid with 
alkali metal carbonates or bicarbonates in presence of water. (Rawlins EA editor, 1995). 
 
 
   
Figure no:15 Effervescent Tablets 
Due to liberation in CO2 gas, the dissolution of API in water as well as taste masking 
effect is enhanced. The advantages of effervescent tablets compared with other oral 
dosage forms includes an opportunity for formulator to improve taste, a more gentle 
action on patient’s stomach and marketing aspects. To manufacture these tablets, either 
wet fusion or heat fusion is adopted. The tablets are compressed soft enough to produce 
an effervescent reaction that is adequately rapid. Water soluble lubricants are used to 
prevent an insoluble scum formation on water surface. To add sweetness to the 
formulation, saccharin is added since sucrose 
is hygroscopic and add too much of bulk to the tablet. The manufacturing shall be done 
under controlled climatic condition to avoid effervescent reaction. The packaging is done 
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under 25% RH at 25ºC. Hands of the consumers and atmospheric moisture after opening 
the container can also result in loss of product quality. The most commonly used 
effervescent tablet today is aspirin tablet. (Lachman L., Liberman L) 
 
1.1.4.2 Hypodermic tablets 
These tablets contain one or more readily water soluble ingredients and are 
intended to be added in water for injection of sterile water to form a clear solution which 
is to be injected parentally. They were widely used by rural physician due to its 
portability. One bottle of sterile water was carried by the doctor to prepare many types of 
injectables. It can be used for medicaments whose stability in water is very poor. 
 
1.1.4.3 Soluble tablets 
Tablets are pre-formed solids of uniform shape and dimensions, usually circular, 
with either flat or convex faces, the distance between faces being less than the diameter. 
Water soluble tablets are intended for application after dissolution in water and contain an 
active ingredient should be totally soluble in water at used concentrations. All the 
excipients used to formulate these tablets are required to be completely soluble in water 
including the glidants, binders, etc. So, manufacturing of this kind of tablets are challenge 
for the formulator. 
Companies manufacturing these tablets have patented them. 
 
 
 
Figure no:16 Soluble Tablets  
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1.2 Manufacturing Methods 
 There are three general methods of tablet preparation. 
 Direct compression method 
 Dry granulation method 
 Wet granulation method 
1.2.1 Direct compression 
Direct compression is the process by which tablets are compressed directly from powder 
mixture of API and suitable excipients. This method of tablet making is of special interest 
for small group of crystalline chemicals having the entire physical characteristic 
necessary for the formulation of a good tablet. (Martinello T,2006) 
 
1.2.2 Dry granulation method 
This process of granulation is also known as Slugging, double compression or 
recompression method. This process of tablet preparation is commonly used when the 
tablet ingredients are sensitive to moisture or are unable to withstand elevated 
temperature during drying. Under such conditions dry granulation is the method of choice 
provided the tablet ingredients have sufficient inherent binding or cohesive properties. 
 
1.2.3 Wet granulation method 
Wet granulation process simply involves wet massing of the powder blend with a 
granulating liquid, wet sizing and drying. (Rawlins EA editor, 1995). 
1.3 Acceptance Criteria for Tablets/Granules 
Bulk density values having less than 1.2 g/cm3 indicates good packing and values 
greater than 1.5 g/cm3 indicates poor packing of tablets. Tablets having values of more 
than 5kg/cm2 indicate good hardness property and the friability limit should be below 1%. 
Acceptance criteria for flow properties of granules like Angle of repose, 
Compressibility index, Hausners ratio is given in the Table 2 and weight variation of 
tablets is given in the Table 3. 
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TABLE :2 ACCEPTANCE CRITERIA OF FLOW PROPERTIES 
 
Compressibility Index 
Angle of Repose 
Range (0) Hausner Ratio Flow Character 
1 – 10 25 – 30 1.00 – 1.11 Excellent 
11 – 15 31 – 35 1.12 – 1.18 Good 
16 – 20 36 – 40 1.19 – 1.25 Fair 
21 – 25 41 -  45 1.26 – 1.34 Passable 
26 – 31 46 – 55 1.35 – 1.45 Poor 
32 – 37 56 – 65 1.46 – 1.59 Very Poor 
> 38 > 66 > 1.60 Very Very Poor 
 
 
 
 
 
TABLE: 3 ACCEPTANCE CRITERIA FOR WEIGHT VARIATION 
 
Average weight of tablet (mg) Percentage difference allowed 
≤130 10 
130-324 7.5 
>324 5 
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1.4 Hypertension Epidemiology 
Cardiovascular diseases such as coronary heart disease and stroke are the largest 
causes of death in developing countries and are one of the main contributors to disease 
burden. Between years 1990 and 2020 these diseases are anticipated to increase by 120% 
for women and 137% for men in developing countries. In India about 70% of coronary 
heart disease-related deaths occur in people younger than 70 years compared with 22% in 
the west and 94% stroke deaths occurs in people less than 70 years in contrast to 6% in 
developed countries. Blood pressure (BP) is directly associated with risks of several types 
of cardiovascular diseases and the associations of BP with disease risk are continuous 
with large proportions of most populations having non-optimal blood pressure values. In 
India cardiovascular diseases cause 5 million deaths annually. Hypertension is directly 
responsible for 57% of all stroke deaths and 24% of all coronary heart disease deaths. 
This fact is important because hypertension is a controllable disease and a 2 mm Hg 
population wide decrease in BP can prevent 151,000 stroke and 153,000 coronary heart 
disease deaths. Better control can lead to prevention of 300,000 of the 1.5 million annual 
deaths from cardiovascular diseases in India. (Rajeev.G,et al,2009). 
1.5 Etiology of Hypertension 
Blood pressure is the force with which blood pushes against the artery walls as it 
travels through the body. Blood pressure is measured by two numbers systolic pressure 
and diastolic pressure. Systolic pressure measures cardiac output and refers to the 
pressure in the arterial system at its highest. Diastolic pressure measures peripheral 
resistance and refers to arterial pressure at its lowest. Blood pressure is normally 
measured at the brachial artery with a sphygmomanometer (pressure cuff) in millimeters 
of mercury (mm Hg) and given as systolic over diastolic pressure. The upper number is 
the systolic pressure, which is the peak force of blood as the heart pumps it. The lower 
number is the diastolic pressure, which is the pressure when the heart is filling or relaxing 
before the next beat. Normal blood pressure for an adult is 120/70 (on average) 
Hypertension, or high blood pressure, is defined as a reading of 140/90 on three 
consecutive measurements at least six hours apart. Hypertension is a major cause of 
stroke. (eHow,2011) 
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1.6 Types of Hypertension 
There are two major types of hypertension and four less frequently found types. 
The two major types are: 
1. Primary or essential hypertension 
2. Secondary hypertension  
The other types include: 
• Malignant Hypertension.  
• Isolated Systolic Hypertension  
• White Coat Hypertension  
• Resistant Hypertension  
1.6.1 Primary or essential hypertension 
Primary hypertension has no specific origin but is strongly associated with 
lifestyle. It is responsible for 90 to 95 percent of diagnosed hypertension and is treated 
with stress management, changes in diet, increased physical activity and medication. 
1.6.2 Secondary hypertension 
Secondary hypertension is responsible for 5 to 10 percent of diagnosed 
hypertension. It is caused by a preexisting medical condition such as congestive heart 
failure, kidney failure, liver failure, or damage to the endocrine (hormone) 
system.(Ehow,2011) 
1.7 Stages of Hypertension 
The concept of “stage of hypertension” was determined in the U.S. by the Joint 
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood 
Pressure .  
There are three stages of hypertension: 
1. Prehypertension 
2. Stage 1 Hypertension 
3. Stage 2 Hypertension  
 
 
 
Table:1 Categories For Blood Pressure Levels In Adults
  
Category  
Normal 
Prehypertension 
Stage 1 Hypertension 
Stage 2 Hypertension 
1.8 Treatment of hypertension
Medications that lower blood pressure are often referred to as antihypertensive 
Generally these drugs are classified
• Diuretics 
• Beta-adrenergic blocking agents
• Calcium channel blockers 
• Angiotensin converting enzyme (ACE) inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Vasodilators  
 
Angiotensin II Receptor Blockers 
The renin-angiotensin s
pathogenesis of essential hypertension, renovascular
failure, and renal diseases associated with albuminuria. Blockade of the rennin
angiotensin system with ACE inhibitors has provided effective treatment of these 
conditions; however, some of the adverse effects of ACE inhibit
to angiotensin II blockade. For example, cough and angioedema are due to other effects 
of ACE inhibition, such as degradation of bradykinins and prostaglandins.
ARBs are used for controlling high blood pressure, treating heart fa
preventing kidney failure in people with diabetes or high blood pressure. They may also 
 
 
Blood Pressure Level (mmHg) 
Systolic    Diastolic  
< 120  < 80 
120-139  80-89 
High Blood Pressure 
140–159  90–99 
160  100 
 
 
 
 
 
 
(ARBs) 
ystem, specifically angiotensinII, is implicated in the 
 hypertension, congestive heart 
ors appear to be unrelated 
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prevent diabetes and reduce the risk of stroke in patients with high blood pressure and an 
enlarged heart. ARBs may also prevent the recurrence of atrial fibrillation. (Rajeev.G,et 
al,2009).  
ARBs have the following actions 
• Dilate arteries and veins and thereby reduce arterial pressure and preload and 
afterload on the heart.  
• Down regulate sympathetic adrenergic activity by blocking the effects of 
angiotensin II on sympathetic nerve release and reuptake of norepinephrine.  
• Promote renal excretion of sodium and water (diuretic effects) by blocking the 
effects of angiotensin II in the kidney and by blocking angiotensin II stimulation 
of aldosterone secretion.  
• Inhibit cardiac and vascular remodeling associated with chronic hypertension, 
heart failure, and myocardial infarction.  
 
McClellan.K et.al.,(1998) 
tolerated when used once daily (as monotherapy
antihypertensive agents) in patients with mild, moderate or severe hypertension.
daily, oral candesartan cilexetil 8 to 32mg dose
blood pressure in patients with mild to moderate essen
showed candesartan cilexetil 16 mg/day to be more effective than losartan potassium 50 
mg/day. Furthermore, the combination of candesartan cilexetil with either 
hydrochlorothiazide or amlodipine resulted in additive antihyperte
data indicate that the tolerability profile of the drug is not significantly different from that 
of placebo, with headache being the most commonly reported event. Adverse events are 
not dose related and are mostly mild to moderate in 
better tolerated than enalapril, primarily because of a reduced incidence of cough, and 
was not associated with the hypokalaemia or hyperuricaemia seen with 
hydrochlorothiazide in a study in patients aged
Stoukides.C et.al.,(1999) reported that candesartan cilexetil provides an alternative 
antihypertensive therapy that is well tolerated and effective in reducing blood pressure
a wide range of patients. Due to its greater binding affinity to the angiotensin II receptor, 
candesartan cilexetil appears to have a longer antihypertensive effect than losartan.The 
study showed that Candesartan cilexetil has demonstrated reductions i
comparable to those of enalapril, with the rate of adverse events greater in the enalapril 
group.  
Erdmann et.al.,(2000) revealed
placebo in the treatment of patients with CHF. This study involved a blinded, independent 
review of all adverse event data and was performed to assess all
unexpected deaths, and hospitali
progression of CHF, other intercurrent events, or accidental injury/attempted suicide. The 
descriptive analysis included crude and cumulative incidence rates for mortality and 
cardiac and non-cardiac morbidit
The results demonstrated a clinically non
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revealed that candesartan cilexetil is effective and well 
 or in combination with other 
-dependently and effectively reduces 
tial hypertension. One study 
nsive effects. Pooled 
severity. Candesartan cilexetil is 
 75 years. 
n blood pressure 
 that candesartan cilexetil is safe when compared with 
-cause mortality and 
zations for acute deterioration of CHF, chronic 
y using the Kaplan-Meier method and the log
-significant trend for all relevant events.
 
  once 
 in 
-rank test. 
 
Homma.K et.al.,(2004) revealed
ACEI/amlodipine proves beneficial than the ARB
disease. Present study compared the effect of the combination therapy with ARB plus 
calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic 
nondiabetic renal disease. At 1 month of the drug trea
(n=19) reduced BP from 154
magnitude of BP reductions was observed with the combination therapy with candesartan 
plus ACEI/amlodipine (from 153
contrast, the reduction in proteinuria was greater with the combination therapy (
at 12 months, n=39) than with the candesartan monotherapy (
reduction in BP was achieved to the same level, the distinct protei
these therapies is attributed to BP
depending on the agents used.
Pfister et.al.,(2004) reported that HD does not influence the elimination kinetics of 
candesartan. The observed inter
pronounced influence of HD-
candesartan makes it mandatory to carefully monitor HD patients treated with 
candesartan cilexetil. It was a repeated
in eight male HD patients over a treatment period of 5 days with an additional 
observation period of 3 days. Pharmacokinetic analysis with nonlinear mixed effects 
modeling (NONMEM) over the whole treatmen
volume of distribution on body weight and of the metabolic clearance on age and body 
weight in the studied population. No significant drug elimination by HD was observed.
Graham.A et.a.l,(2004) revealed
drug when used alone or in combination with amlodipine or amlodipine plus 
hydrochlorothiazide in the treatment of moderate
study evaluated the efficacy
antagonist, used alone or in combination with amlodipine or
amlodipine and hydrochlorothiazide in the
essential hypertension. The result of the study demo
effective BP-lowering drug when used alone
amlodipine plus hydrochlorothiazide
Literature review
 that combination therapy with ARB plus 
 monotherapy in nondiabetic renal 
tment, the candesartan monotherapy 
3/93 2 to 146 3/88 2 mmHg (P<0.05), and a similar 
2/95 2 to 144 2/88 2 mmHg, P<0.05,
-25 3%, n=19) Since the 
nuria-sparing action of 
-independent mechanisms, which should vary 
 
- and intra individual variability of oral clearance and the 
induced volume contraction on the haemodynamic effects of 
 dose study (8 mg candesartan cilexetil once daily) 
t period revealed a dependency of the 
 that candesartan cilexetil is an effective BP
-to-severe essential hypertension. This 
 of candesartan cilexetil, an angiotensin II type 1 receptor 
 in combination with 
 treatment of patients with moderate
nstrated that candesartan
 or in combination with amlodipine or 
 and was well tolerated throughout the investigation.
 
 n=39). In 
-52 3% 
 
-lowering 
-to-severe 
 is an 
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Toblli.J et.al.,(2004) reported that candesartan cilexetil provides a significant protective 
role against morphologic changes in vessels as well as in cavernous spaces of the erectile 
tissue, caused by high blood pressure, in SHR. This present study was performed to 
determine whether an angiotensin II receptor blocker could protect cavernous tissue (CT) 
from these structural alterations in SHR.Male SHR and Wistar-Kyoto (WKY) rats were 
studied during 4 months. Rats were divided into three groups: SHR (n=10), SHR with 
candesartan cilexetil (n=10) and WKY rats (n=10). Candesartan cilexetil 7.5 mg/kg/day 
was administered orally throughout the study. CT was processed for pathology studies. 
The amount of (1) cavernous smooth muscle (CSM), (2) vascular smooth muscle (VSM), 
(3) collagen type III, and the rat endothelial cell antibody (RECA-1)/tunica media ratio in 
cavernous arteries were evaluated. 
See.S et.al.,(2008) reported that candesartan cilexetil is an effective antihypertensive 
agent that can be used alone or in combination with other antihypertensive drugs. It is 
generally well tolerated and may be an option for patients who cannot tolerate 
angiotensin-converting-enzyme inhibitors because of cough.  In clinical trials, 
candesartan cilexetil has produced a dose-dependent effect when given in dosages of 2-32 
mg/day. Observed trough-to-peak blood pressure ratios support a once-daily dosage 
regimen. The antihypertensive effect of candesartan cilexetil 4-16 mg/day was as great as 
that of enalapril 10-20 mg/day and amlodipine 5 mg/day and larger than that of losartan 
potassium 50 mg/day. Adding candesartan cilexetil to hydrochlorothiazide 12.5-25 
mg/day and amlodipine 5 mg/day led to enhanced blood-pressure reductions and was well 
tolerated.  
Vijay.N et.al.,(2008) revealed that the wet bead milling process coupled with spray 
granulation is a viable approach for developing nanoparticle formulations of 
biopharmaceutics classification system (BCS) class II compounds with enhanced 
solubility and faster dissolution. In this study the granules containing drug nanoparticles 
of KC, FF and CC were blended with extra-granular excipients using a double cone 
blender. The blend was subsequently compressed into tablets at the desired strength, and 
the physical properties of tablets — hardness, friability and disintegration time — were 
measured. Enhancing solubility and dissolution velocity of sparingly soluble compounds 
correlates with an improved pharmacokinetics profile and a concomitantly improved 
therapeutic outcome. 
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Franks et.al.,(2008) reported that candesartan cilexetil effectively reduced BP as 
demonstrated by CBPM and ABPM measurements and was well tolerated in this group of 
hypertensive children. In this study, eleven patients (mean age 14.2 y) received a final 
candesartan cilexetil median daily dose of 8 mg (0.13 mg/kg, range 2–16 mg). Study 
treatment resulted in significant reductions in systolic and diastolic BP as measured by 
CBPM (–7.4%, p = 0.03 and –5.9%, p = 0.01, respectively) and by ABPM (–6.0%, p = 
0.03 and –10.8%, p = 0.006, respectively), but no significant reductions as measured by 
HBPM. No clinically significant changes in laboratory measures were observed and 
patients reported nonspecific mild adverse effects. 
See.S et.al.,(2008) reported that candesartan cilexetil is an effective antihypertensive 
agent that can be used alone or in combination with other antihypertensive drugs. It is 
generally well tolerated and may be an option for patients who cannot tolerate 
angiotensin-converting-enzyme inhibitors because of cough.  In clinical trials, 
candesartan cilexetil has produced a dose-dependent effect when given in dosages of 2-32 
mg/day. Observed trough-to-peak blood pressure ratios support a once-daily dosage 
regimen. The antihypertensive effect of candesartan cilexetil 4-16 mg/day was as great as 
that of enalapril 10-20 mg/day and amlodipine 5 mg/day and larger than that of losartan 
potassium 50 mg/day. Adding candesartan cilexetil to hydrochlorothiazide 12.5-25 
mg/day and amlodipine 5 mg/day led to enhanced blood-pressure reductions and was well 
tolerated. 
Jean.B et.al.,(2009) revealed that candesartan significantly reduces the incidence of 
cardiovascular death, hospital admissions for decompensated heart failure, and all-cause 
mortality in chronic heart failure patients with altered left ventricular systolic function, 
when added to standard therapies or as an alternative to ACE inhibitors when these are 
poorly tolerated.Furthermore, the study showed that candesartan can protect against 
myocardial infarction, atrial fibrillation and diabetes. Tolerance to candesartan is good, 
but blood pressure and serum potassium and creatinine levels must be monitored. 
Baguet.J et.al.,(2009) reported that candesartan and amlodipine besylate treatments may 
alter identically the natural progression of carotid IMT in hypertensive type 2 diabetic 
patients. This study consists of 36 months and investigated the effect of candesartan 
cilexetil(CC) on the common carotid intima-media thickness (IMT) vs amlodipine 
besylate (AML) in patients with type 2 diabetes and mild to moderate essential 
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hypertension.No significant differences were observed between the two groups for 
change in IMT at M12 (−0.001 vs −0.027 mm/year for CC and AML respectively, p = 
0.425), at M24 (−0.033 vs −0.019 mm per year respectively, p = 0.442). The 
augmentation in carotid lumen diameter from baseline was statistically greater in the 
AML group at the last visit (p = 0.034). BP variations during the study were similar in the 
two groups. 
Fang .G et.al.,(2010) reported that the nanoemulsion was very effective for enhancing the 
oral absorption of insoluble candesartan cilexetil, candesartan cilexetil loaded 
nanoemulsionshowed the great potential for clinical application. In this work, a novel 
candesartan cilexetil loaded nanoemulsion (CCN) was designed to improve the intestinal 
absorption. candesartancilexetil loaded nanoemulsion was prepared by a modified 
emulsification-solvent evaporation technique. The physicochemical characteristics of 
candesartan cilexetil loaded nanoemulsion were characterized, and the intestinal 
absorption was investigated as well. The experimental results indicated that candesartan 
cilexetil loaded nanoemulsion was nanometer-sized droplets (35.5 ± 5.9 nm) with 
negative potential (− 6.45 ± 0.36 mV), and the absorption of candesartan cilexetil loaded 
nanoemulsion was significantly improved in total intestinal tract compared with free 
candesartan cilexetil solution. The experimental results showed that the area under the 
concentration–time curve (AUC0–t) of candesartan was improved over 10-fold after 
candesartan cilexetil was incorporated into candesartan cilexetil loaded nanoemulsion..  
Omari et.al.,(2010) revealed that complex formation of candesartan with β-cyclodextrins 
prepared by freeze drying method is chemically not stable due to the formation of 
amorphous candesartan and compression enhances the instability of candesartan. In this 
study the DSC thermograms for CAND/β-CyD complexes proved the formation of 
inclusion complexes with new solid phase. MM studies indicate the partial penetration of 
candesartan into the β-CyD cavity. 
Akira.M,(2010) reported that candesartan cilexetil, 8 mg/day, significantly reduced the 
progression of CHF when compared with placebo. This 6-month study examined the 
safety and efficacy of candesartan cilexetil, 8 mg once daily, to prevent the progression of 
congestive heart failure (CHF). 
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3.AIM & OBJECTIVES 
Aim: 
The aim of the present study is to develop and evaluate candesartan cilexetil 
tablets with respect to reference sample. The formulation of tablets were done match the 
in-vitro drug release with respect to the reference drug and carry out stability studies . 
Objective: 
1. To formulate and evaluate immediate release candesartan cilexetil tablets (32mg). 
Specific Objectives: 
1. To perform preformulation studies including drug – excipient compatibility study. 
2. To develop various formulations with different excipients. 
3. To establish the invitro release compliance with the established criteria. 
4. To establish the stabilityof the formulation. 
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4.PLAN OF WORK 
Figure No:17 Plan of Work 
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5.EXPERIMENTAL INVESTIGATION 
5.1 DRUG PROFILE 
Physiochemical, Pharmacological and Pharmacokinetic nature of the candesartan 
cilexetilis given in Tables 4 - 6.(Merk Manuals,2009).The reference product 
specifications are given in Table 7. 
TABLE: 4 PHYSIOCHEMICAL NATURE OF CANDESARTAN 
S.No Physiochemical Nature Description 
1 Common Name Candesartan cilexetil 
2 Nature Prodrug 
3 State Solid 
4 Colour White to off white 
5 Taste Sour to bitter 
6 IUPAC Name 
2-ethoxy-3-[[4-[2-(2H-tetrazol-5 
yl)phenyl]phenyl]methyl]benzimidazole-4-
carboxylic acid 
7 Molecular Formula C24H20N6O3 
8 Chemical Structure 
 
9 Molecular Weight 610.659660 [g/mol] 
10 Melting Point 1630C 
11 Solubility Sparingly soluble in methanol, insoluble in water 
12 Predicted Water Solubility 7.71 mg/mL 
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TABLE: 5 PHARMACOLOGICAL NATURE OF CANDESARTAN 
 
S.No 
Pharmacological  
Nature 
Description 
1 Indication For the treatment of hypertension and Heart Failure. 
2 Mechanism of Action 
Candesartan competes with angiotensin II for binding at the 
AT1 receptor subtype. As angiotensin II is a vasoconstrictor which 
also stimulates the synthesis and release of aldosterone, blockage of 
its effects results in a decrease in systemic vascular resistance. 
3 Drug Interactions 
 
Amiloride Increased risk of hyperkaliemia 
Drospirenone Increased risk of hyperkaliemia 
Lithium The ARB increases serum levels of lithium 
Potassium Increased risk of hyperkaliemia 
Spironolactone Increased risk of hyperkaliemia 
Triamterene Increased risk of hyperkaliemia 
4 
Phase 1 Metabolizing 
Enzymes 
Cytochrome P450 11B2 (CYP11B2) 
5 Targets Type-1 angiotensin II receptor 
6 BCS    Class II - Low Solubility and High Permeability 
 
(Ogihara T, 1994) 
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TABLE:6 PHARMACOKINETIC NATURE OF CANDESARTAN 
 
S.No Pharmacokinetic Nature Description 
1 Absorption Bioavailability is about 15% 
2 Distribution Vd is 0.13 L/kg 
3 Metabolism 
Candesartan cilexetil is bioactivated by ester 
hydrolysis during absorption from the GI tract to 
candesartan. Candesartan undergoes minor hepatic 
metabolism by O-deethylation to an inactive 
metabolite 
4 Elimination 
Primarily as unchanged drug in the urine and by 
the biliary route, in the feces. Plasma Cl is 0.37 
mL/min/kg. Renal Cl is 0.19 mL/min/kg. 
About 26% is excreted unchanged in urine. 
5 T max 3 to 4 hrs 
6 Half Life (t ½)  9 hrs 
7 Protein binding More than 99% 
8 Toxicity 
No lethality was observed in acute toxicity studies 
in mice, rats and dogs given single oral doses of up 
to 2000 mg/kg of candesartan cilexetil 
         (Van Lier Jet.al,1997) 
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TABLE:7 REFERENCE PRODUCT SPECIFICATIONS OF CANDESARTAN 
 
S.No Product Specifications Description 
1 Drug Type  Approved 
2 Dosage Form Tablet 
3 Route of Administration Oral 
4 Strength 4mg, 8mg, 16mg and 32mg 
5 Non active Ingredients 
Calcium CMC, maize starch, HPC, iron 
oxide lactose, magnesium stearate, PEG, 
Avicel. 
6 Package Blister Pack 
7 Storage Conditions Controlled room temperature 
8 Available Brands Amias, Atacand, Blopress, Ratacand 
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5.2 EXCIPIENT PROFILE 
A. MICROCRYSTALLIN CELLULOSE: 
Synonyms: Avicel PH, Celex, Cellulose gel, Celphere, Ceolus KG, crystalline cellulose. 
Functional Category: Adsorbent, suspending agent, tablet and capsule diluent, tablet 
disintegrant. 
Applications: Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
a binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. In addition to its use as a binder/diluent, 
microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting. 
Description: Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particle sizes and moisture grades that have 
different properties and applications. 
Stability and Storage Conditions: Microcrystalline cellulose is a stable though 
hygroscopic material. The bulk material should be stored in a well-closed container in a 
cool, dry place. 
Solubility: Slightly soluble in 5% w/v NAOH solution, practically insoluble in water, 
diluent acids and most organic solvents. 
Stability: It is stable though Hygroscopic material. 
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing 
agents.(Raymond.C et al,2009) 
 
 Experimental Investigation 
Padmavathi College of Pharmacy and Research Institute 40 
B. STARCH PREGELATINIZED 
Synonyms: Compressible starch, Instastarch 
Description: Pregelatinized starch occurs as a moderately coarse to fine, white to off-
white colored powder. It is odorless and has a slight characteristic taste. 
Functional Category: Tablet and capsule diluent, tablet and capsule disintegrant; tablet 
binder. 
Applications: Pregelatinized starch is a modified starch used in oral capsule and tablet 
formulations as a binder, diluent, and disintegrant. 
Stability and Storage Conditions: Dry, unheated starch is stable if protected from high 
humidity. When used as a diluent or disintegrant in solid-dosage forms, starch is 
considered to be inert under normal storage conditions. However, heated starch solutions 
or pastes are physically unstable and are readily attacked by microorganisms to form a 
wide variety of starch derivatives and modified starches that have unique physical 
properties. Starch should be stored in an airtight container in a cool, dry 
place.(Raymond.C et al,2009) 
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C. HYDROXYPROPYL CELLULOSE 
Synonyms: Cellulose, hydroxypropyl ether; hydroxypropylcellulosum; hyprolose; klucel 
Functional Category: Coating agent; emulsifying agent; stabilizing agent; suspending 
agent; tablet binder; thickening agent; viscosity-increasing agent. 
Description: Hydroxypropyl cellulose is a white to slightly yellow-colored, odorless and 
tasteless powder 
Applications: In oral products, hydroxypropyl cellulose is primarily used in tableting as a 
binder, film-coating and extended-release-matrix former. Concentrations of 
hydroxypropyl cellulose of 2–6% w/w may be used as a binder in either wet-granulation 
or dry, direct compression tableting processes. 
Stability: Hydroxypropyl cellulose powder is a stable material, although it is hygroscopic 
after drying. 
 
Incompatibilities: Hydroxypropyl cellulose in solution demonstrates some 
incompatibility with substituted phenol derivatives, such as methyl paraben and propyl 
paraben. (Raymond.C et al,2009) 
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D. LACTOSE MONOHYDRATE 
 
Synonyms:CapsuLac; GranuLac; Lactochem; lactosummonohydricum; Monohydrate; 
Pharmatose; PrismaLac; SacheLac 
 
Functional Category: Dry powder inhaler carrier; lyophilization aid; tablet binder; tablet 
and capsule diluent; tablet and capsule filler. 
 
Applications: Lactose is widely used as a filler and diluent in tablets and capsules, and to 
a more limited extent in lyophilized products and infant formulas. 
 
Description: Lactose occurs as white to off-white crystalline particles or powder. Lactose 
is odorless and slightly sweet-tasting. 
 
Storage: Mold growth may occur under humid conditions (80% relative humidity and 
above). Lactose may develop a brown coloration on storage. 
 
Incompatibilities: A Maillard-type condensation reaction is likely to occur between 
lactose and compounds with a primary amine group to form brown or yellow-brown-
colored products..(Raymond.C et al,2009) 
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E. CALCIUM CARBOXYMETHYLCELLULOSE 
 
Synonyms: Calcium carboxymethylcellulose; calcium cellulose glycolate; carmellosum 
calcium; CMC calcium 
 
Functional Category: Emulsifying agent; coating agent; stabilizing agent; suspending 
agent; tablet and capsule disintegrant; viscosity-increasing agent; water-absorbing agent. 
 
Applications: The main use of carboxymethylcellulose calcium is in tablet formulations 
as a binder, diluent, and disintegrant. 
 
Description: Carboxymethylcellulose calcium occurs as a white to yellowish white, 
hygroscopic, odorless powder. 
 
Stability and Storage Conditions: Carboxymethylcellulose calcium is a stable, though 
hygroscopic material. It should be stored in a well-closed container in a cool, dry place. 
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F. MAGNESIUM STEARATE 
 
Synonyms: Dibasic magnesium stearate; magnesium distearate; magnesiistearas; 
magnesium octadecanoate; octadecanoic acid 
 
Functional Category: Tablet and capsule lubricant. 
 
Description: Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. 
 
Applications: It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w.(Raymond.C et al,2009) 
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5.3 MATERIALS AND METHODS 
TABLE: 8 MATERIALS USED IN THE FORMULATION 
S.No Ingredients Rationale Source 
1. 
Candesartan Cilexetil 
 
API 
Aurabindo  
Pharmaceutical co.ltd 
Hyderabad 
2. Lactose Monohydrate Diluent 
Avon organics Ltd 
Mumbai 
3. Pre GelatinizedStarch Filler/Binder 
Aurabindo  
Pharmaceutical Ltd 
Hyderabad 
4. 
Microcrystalline cellose    
(Avicel PH 101) 
Disintegrant 
SD Fine Chemicals ltd 
Mumbai 
5. Klucel– LF Binder 
SD Fine Chemicals ltd 
Mumbai 
6 
Calcium. CarboxyMethyl 
Cellulose 
Superdisintegrants 
SD Fine Chemicals ltd 
Mumbai 
7 Mg. Stearate Glident 
SD Fine Chemicals ltd 
Mumbai 
8 Purified water Solvent 
NATCO Pharma Ltd 
Hyderabad 
9 PEG 6000 Suspending agent 
SD Fine Chemicals ltd 
Mumbai 
10 Ferric oxide Coloring agent 
SD Fine Chemicals ltd 
Mumbai 
11 Pvp-k30 Binder 
SD Fine Chemicals ltd 
Mumbai 
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The list of equipments used for the formulation of candesartan immediate release tablets 
are given in Table. 
TABLE:9 EQUIPMENTS USED FOR THE FORMULATION 
 
 
 
Name of instrument Model no. Make 
Electronic Weighing Balance PR 203 Mettler Toledo Mumbai 
Tap Density Tester USP ETD-1020 Electrolab Mumbai 
Electromagnetic  Sieve Shaker EMS-8 Electrolab Mumbai 
Electronic Moisture Analyzer HG 63 Mettler Toledo Mumbai 
Tablet Compression Machine-8 
station MINI Press - II MT 
Rimek 
Gujarat 
Digital Hardness Tester TH 10503 Labindia Bangalore 
Disintegration Test Apparatus USP ED-2AL Electrolab Mumbai 
Friabilator USP EF-2 Electrolab Mumbai 
Mechanical Stirrer RQT-124D Remi Motors Mumbai 
Pharma R&D Coater Deluxe Ideal Cures Mumbai 
Fluid Bed Drier UT-150 UmangPharmatech Mumbai 
Rapid mixture granulator RMG 25 Anchormark Mumbai 
Multi Mill MM 15 Anchormark Mumbai 
Weighing balance T-26I Scaletec Instruments (Citizen) Mumbai 
Tray Drier PPT TD6 Platinum Pharmatech Mumbai 
Dissolution  Test Apparatus Type II UV-Pharmaspec – 1700 DBK Instruments Ltd., Mumbai. 
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5.4 PREFORMULATION STUDIES 
Preformulation may be described as a stage of development during which the 
physicochemical and biopharmaceutical properties of a drug substance are characterized. 
It is an important part of the drug development process. The information relating to drug 
development acquired during this phase is used for making critical decisions in 
subsequent stages of development. A wide variety of information must be generated to 
develop formulations rationally. Characterization of the drug is a very important step at 
the preformulation phase of product development followed by studying the properties of 
the excipients and their compatibility. (E.F. Fiese ,1986) 
 
The API was tested for the following properties 
• Organoleptic Properties 
• Solubility 
• Water Content 
• Particle Size determination 
• Flow Properties 
o Angle of Repose 
o Bulk Density 
o Tapped Density 
o Carr’s Index 
o Hausner’s Ratio 
• Drug – Excipient compatibility study 
5.4.1 Organoleptic Properties 
The drug sample was viewed visually and viewed under the compound 
microscope for the determination of its color using the black and white backgrounds and 
nature of the drug sample. Then the results were compared with the official books. 
 
5.4.2 Solubility 
The solubility of the drug sample was carried out in different solvents (aqueous and 
organic) according to the United States Pharmacopoeia. The results are then compared 
with those given in the United States Pharmacopoeia.( G. Bankeret.al,2000) 
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5.4.3 Water Content 
Methanol (35ml) was transferred to the titration vessel and titrated with Karl 
fisher reagent to the electrometric end point to consume any moisture that may be present. 
300-500mg of API was transferred to the titration vessel and titrated with Karl fisher 
reagent to the electrometric endpoint. Water content present in the sample was calculated 
by the formulae: (E.F. Fiese ,1986) 
Calculation: 
 
 
 
Where, 
 S = Volume in ml of reagent consumed in the second titration 
 F = Water equivalent factor of KF reagent 
 W = Weight of sample taken in mg 
 
5.4.4 Flow Properties 
5.4.4.1 Angle of repose (θ) 
It is a direct measure of flow property of powders. It is the maximum angle that 
can be obtained between the free standing surface of a powder heap and the horizontal. 
Angle of repose was determined using funnel to pour the powder on the surface 
from a fixed height of 2cm. Circumference was drawn with a pencil on the graph paper 
and the radius of base of a pile was measured at 5 different points and average was taken 
for calculatingAngle of repose using following formula: 
 
 
Angle of Repose (Θ) = Tan-1 (h/r) 
                            Where, 
                               h = height of a pile (2 cm)  
                          r = radius of pile base. 
 
 
 
Water (%) = S X F X 100 
        W 
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5.4.4.2 Bulk density 
It is the ratio of given mass of powder and its bulk volume determined by 
measuring the volume of known mass of powder sample that has been passed through the 
screen in to graduating cylinder. (E.F. Fiese ,1986) 
Bulk density was determined according to USP method I. The powder sample under test 
was screened through sieve no 18 and 10 gm of pure drug was accurately weighed and 
filled in a 100ml graduated cylinder and the powder was leveled and the unsettled volume 
(Vo) was noted. Bulk density (Db) was calculated in g/ml by the formula:  
 
(Db)= M/Vo 
Where, 
         M = mass of powder taken 
  Vo= unsettled apparent volume 
5.4.4.3 Tapped density 
Tapped density was determined by USP method II. The powder sample under test 
was screened through sieve no.22 and 10 gm of pure drug was filled in 100ml graduated 
cylinder of tap density tester (electrolab, ETD 1020). The mechanical tapping of the 
cylinder was carried out using tapped density tester at a normal rate of 250 drops per 
minute for 500 times initially and the initial tapped volume (Va) was noted. Tapping was 
proceeded further for additional 750 times and volume was noted. The difference between 
two tapping volumes was calculated.  
Tapping was continued for additional 250 tap if the difference is more than 2%. This was 
continued in increments of 250 taps until differences between volumes of subsequent 
tapping was less than 2%. This volume was noted as, the final tapped volume (Vo). The 
tapped density (Dt) was calculated in g/ml by the formula: 
 
Dt = M/ Vo 
                                                   Where,  
  M= weight of sample powder 
                                                                                             
Vo = final tapped volume 
\ 
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5.4.4.4  Compressibility Index and Hausner Ratio 
Compressibility index and hausner ratio are measures of the propensity of a 
powder to be compressed and provide relative importance of inter particulate interactions. 
The free flowing powder has less inter particulate interactions and bulk & tapped density 
difference is close when compared to poorer flowing materials. (E.F. Fiese ,1986) 
Carr’s index i.e., % compressibility indicates the flow property and packing ability of the 
tablet. It was determined by measuring both the bulk and tapped density of a powder. 
Compressibility Index was calculated using following equation: 
 
CI (%) = [(Dt-Db)/Dt] x100 
   Where, 
Dt = tapped density 
Db = bulk density 
Hausner’s ratio was calculated using the formula: 
Hausner Ratio = Dt/Db 
Where, 
Dt = tapped density 
Db = bulk density 
 
 
5.4.5 Drug – Excipient Compatibility Study 
 Drug is in intimate contact with one or more excipient in all the dosage forms. 
Later it could affect the stability of drug. Knowledge of drug excipient interaction is 
useful in selecting an appropriate excipient.  
API and excipients are taken in the ratios as mentioned in Table 10 and mixed together in 
a polybag for 5 min. Each sample mixture is divided into four parts (1gm each), 
transferred in to a glass vial and stored in different conditions as shown in Table 11. 
All vials are properly sealed and loaded at respective conditions. The samples are checked 
for its description, related substance and water content by karlfisher. 
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TABLE: 10 DRUG AND EXCIPIENT RATIO FOR COMPATIBILITY STUDIES 
 
S.No Drug - Excipient Ratio 
1 Candesartan + Corn starch 1:5 
2 Candesartan + PEG 6000 1:5 
3 Candesartan + Calcium CMC  1:5 
4 Candesartan + Klucel EF 1:5 
5 Candesartan + Klucel LF 1:5 
6 Candesartan + Ferric oxide red 1:0.1 
7 Candesartan + Magnesium stearate 1:1 
8 Candesartan + Avicel 1:5 
9 Candesartan + Lactose 1:5 
 
The prepared drug and excipient mixtures were evaluated at various intervals (As 
mentioned in Table 11) forphysical appearance, change in color and related substances by 
HPLC. 
 
TABLE: 11 SAMPLING SCHEDULE 
S.No Condition Duration No. of Sets 
1 Initial 0 days 1 
2 550C ± 20C 14 days 1 
3 40 ± 20C & 75 ± 5% RH 14 days 1 
4 40 ± 20C & 75 ± 5% RH 28 days 1 
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5.4.6 PREPARATION OF STANDARD CURVE 
 Candesartan cilexetil (100 mg) was accurately weighed and dissolved in 100 
ml of ethanol to give stock solution (1000 mcg/ml). 
 
 Aliquots of 1000 mcg/ml solution were suitably diluted with methanol To give 
final concentrations of 5, 10, 15, 20 and 25 mcg/ml. 
 
 The λ max was found by UV spectrum of Candesartan cilexetil in methanol, in 
the range of 200-400 nm, and it was found to be 255 nm. 
 
 Absorbance was measured at 255 nm against methanol as a blank. Spectral 
characteristics of Candesartan cilexetil and linearity data are given in table. 
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TABLE:12 SPECTRAL CHARACTERISTICS OF CANDESARTAN CILEXETIL 
 
 
 
Parameters 
 
 
Value 
 
λmax(nm) 
 
 
255 
 
Beer’s law limits (mcg/ml) (c) 
 
 
5-25 
 
Molar absorptivity (lit/mol-1 cm-1) 
 
 
2.0275304×104 
 
Regression equation (Y*) 
 
 
Y=0.03401x-0.00847 
 
Slope (m) 
 
 
3.4011×10-2 
 
Y - intercept (c) 
 
 
8.4761×10-3 
 
Correlation coefficient (r2) 
 
 
0.9998 
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TABLE:13 STANDARD CURVE OF CANDESARTAN CILEXETIL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration(mcg/ml) 
 
Absorbance 
 
0 
 
0.000 
 
5 
 
0.175 
 
10 
 
0.352 
 
15 
 
0.526 
 
20 
 
0.704 
 
25 
 
0.898 
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Figure no:18 UV spectrum of Candesartan cilexetil in methanol 
 
 
 
 
Figure no:19 Standard curve of Candesartan cilexetil 
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5.4.7 Identification of drug by FTIR 
The identification of drug was done by FTIR Spectroscopy. 
 
Method: 
            Triturate 1-2mg of the substance to be examined with 300-400 mg,unless 
otherwise specified, of finely powdered and dried potassium bromide R or potassium 
chloride R. These quantities are usually sufficient to give a disc of 10-15 mm diameter 
and a spectrum of suitable intensity.Infrared spectrophotometers are used for recording 
spectra in the region of 4000-650 cm-1 
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Figure no:20 FTIR spectrum of Candesartan cilexitil 
 
            IR REGION: 
Functional group Region range 
N-H-Streching 3600-3200 
C-H-Streching 2960-2850 
C=O-Streching 1600-1450 
C-N-Vibrations 1400-1040 
C-O-Bending 900-650 
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Figure no:21 FTIR spectrum of candesrtan granules 
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5.5 FORMULATION OF CANDESARTAN IR (32MG) TABLETS 
 
5.5.1 Formulation Planning 
The immediate release tablets containing 32mg candesartan cilexetil were prepared with a 
total tablet weight of 260mg.Based on the results of preformulation studies; to improve 
the flow properties, tablets were prepared by wet granulation technique and the 
composition is given in Table 14. Based on literature survey and compatibility tests 
excipients like microcrystalline cellulose (pH 101), poly ethylene glycol – 6000, pre 
gelatinized starch, hydroxypropylcellulose, carboxymethyl cellulose, magnesium stearate 
were used. 
5.5.2 Manufacturing Procedure 
• Weighed candesartan, lactose and pre gelatinized starchwas passed through 40 mesh 
and then mixed.  
• Weighed poly ethylene glycol 6000 was transferred into 50ml of purified water and 
then stirred by using mechanical stirrer to get clear solution. 
• Weighed klucel was poured in to above poly ethylene glycol solution and then stirred 
to get turbid solution by using mechanical stirrer. 
• Above blend was made into dough mass by using binder solution. 
• Dough mass was passed through 14 mesh to get wet granules and dried by using FBD 
at 60oc. 
• Dried granules were passed through 18 mesh. 
• Weighed Cal.CMC and Mg.Stearate was passed through 40 mesh and then added to 
above granules and lubricated granules were compressed by rotary die press. 
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5.5.3 Compositions Formulations of Candesartan Cilexetil 
The immediate release tablets of candesartan cilexetil 32mg has been formulated 
using the formula shown in the Table. 
 
 TABLE:14 COMPOSITIONS OF FORMULATIONS 
Ingredients F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 
Candesartan 32 32 32 32 32 32 32 32 32 32 
Lactose 
Mono 
Hydrate 
155.98 155.98 164.97 164.97 166.97 145 52 52 - 164.97 
PEG 6000 
 
12 12 6 2 - 12 12 12 - 6 
Lycatab PGS/  
Corn starch 
40 40 40 40 40 40 - 25 25 40 
Ferric oxide 
Red 
0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
Hydroxy 
propyl 
cellulose 
8 8 8 12 12 10 12 12 12 8 
PVP – K 30 - - - - - 7.8 - - - - 
Micro 
crystalline 
cellulose 
- - - - - - 125 100 150 - 
Purified 
Water 
70 70 70 70 70 70 70 70 120 70 
Ca CMC 11.2 11.2 8 2 8 - 25 25 25 8 
Mg.stearate 0.8 0.8 1.0 1 1 2.6 2 2 2 1.0 
SLS - - - - - 10 - - - - 
Total (mg) 260 260 260 260 260 260 260 260 260 260 
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6. EVALUATION STUDIES 
6.1 Evaluation of granules 
6.1.1 Flow Properties 
6.1.1.1 Angle of repose (θ) 
It is a direct measure of flow property of powders. It is the maximum angle that 
can be obtained between the free standing surface of a powder heap and the horizontal. 
Angle of repose was determined using funnel to pour the powder on the surface 
from a fixed height of 2cm. Circumference was drawn with a pencil on the graph paper 
and the radius of base of a pile was measured at 5 different points and average was taken 
for calculatingAngle of repose using following formula 
 
 
Angle of Repose (Θ) = Tan-1 (h/r) 
                            Where, 
                               h = height of a pile (2 cm)  
                          r = radius of pile base. 
 
6.1.1.2 Bulk density 
It is the ratio of given mass of powder and its bulk volume determined by measuring the 
volume of known mass of powder sample that has been passed through the screen in to 
graduating cylinder. (L.J. Ravin et.al,1990) 
Bulk density was determined according to USP method I. The powder sample 
under test was screened through sieve no 18 and 10 gm of pure drug was accurately 
weighed and filled in a 100ml graduated cylinder and the powder was leveled and the 
unsettled volume (Vo) was noted. Bulk density (Db) was calculated in g/ml by the 
formula:  
 
(Db)= M/Vo 
Where, 
         M = mass of powder taken 
       Vo= unsettled apparent volume 
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6.1.1.3 Tapped density 
Tapped density was determined by USP method II. The powder sample under test 
was screened through sieve no.22 and 10 gm of pure drug was filled in 100ml graduated 
cylinder of tap density tester (electrolab, ETD 1020). The mechanical tapping of the 
cylinder was carried out using tapped density tester at a normal rate of 250 drops per 
minute for 500 times initially and the initial tapped volume (Va) was noted. Tapping was 
proceeded further for additional 750 times and volume was noted. The difference between 
two tapping volumes was calculated. (L.J. Ravin et.al,1990) 
Tapping was continued for additional 250 tap if the difference is more than 2%. This was 
continued in increments of 250 taps until differences between volumes of subsequent 
tapping was less than 2%. This volume was noted as, the final tapped volume (Vo). The 
tapped density (Dt) was calculated in g/ml by the formula: 
 
Dt = M/ Vo 
                                                   Where,  
  M= weight of sample powder 
                                                                                             
Vo = final tapped volume 
 
6.1.1.4  Compressibility Index and Hausner Ratio 
Compressibility index and hausner ratio are measures of the propensity of a 
powder to be compressed and provide relative importance of inter particulate interactions. 
The free flowing powder has less inter particulate interactions and bulk & tapped density 
difference is close when compared to poorer flowing materials. 
Carr’s index i.e., % compressibility indicates the flow property and packing ability of the 
tablet. It was determined by measuring both the bulk and tapped density of a powder. 
Compressibility Index was calculated using following equation 
 
CI (%) = [(Dt-Db)/Dt] x100 
   Where, 
Dt = tapped density 
Db = bulk density 
 
Evaluation Studies 
 
Padmavathi College of Pharmacy and Research Institute 63 
 
Hausner’s ratio was calculated using the formula: 
Hausner Ratio = Dt/Db 
Where, 
Dt = tapped density 
Db = bulk density 
 
6.2 Evaluation of tablets 
6.2.1 Weight variation 
Weight variation was calculated as per method descried in USP. Twenty tablets 
were selected at random and their average weight was determined using an electronic 
balance. The tablets were weighed individually and compared with average weight.( 
Seitz, J. A. et.al, 1965) 
 
6.2.2 Tablet thickness and Hardness 
Thickness was measured using venier caliper and hardness of formulations were 
measured using a Hardness Tester. Ten tablets of each trial formulation were taken and 
measured individually at frequent intervals. 
 
6.3.3 Friability (%) 
Friability was determined by taking 20 tablets. Tablets samples were weighed 
accurately and placed in friabilator after the given specification (4 min at 25 rpm). The 
tablets were weighed again and % friability was then calculated by: 
 
%F = {(W – W0)/W} x 100 
     Where,  
% F  = Friability of tablets in percent.  
   W  = Initial Wight of tablets. 
WO = Final weight of tablets. 
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6.3.4 Disintegration Test 
Disintegration test was measured using USP tablet disintegration test apparatus (ED2AL, 
Electrolab, India) by using 900 ml of distilled water at room temperature (37±20C). 
(Odeku et.al,2003) 
6.3.5 Assay (HPLC) 
6.3.5.1 Chromatographic conditions 
Column  : Hypersill BDS-C8 (150 X 4.6mm) 5µm 
Flow rate   : 1.5ml/min 
Wave length  : UV-210nm 
Injection volume : 10µL 
Column temperature : 40oC 
Run time  : 25min 
Blank, standard and sample preparations of equal volume were separately injected 
and the chromatograms are recorded. The content (%) of candesartan in the portion of 
candesartan tablet was calculated by the formula: (Odeku et.al,2003) 
 
6.3.5.2 Calculation 
% of content of candesartan cilexetil 
 
 
 
Where, 
 SA = Peak area response due of candesartan from standard preparation 
 TA =  Peak area response due of candesartan from sample preparation 
 SW = Weight of candesartan working standard (mg) 
 P = Purity of candesartan working standard 
 TW = Weight of sample 
 LA = Label amount 
 
 
 
 
 
TA   X    SW    X      5      X     100      X   100X    P   XAvgWt    X    100 
SA           100           50    TW               2              100  LA 
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6.3.6 In-vitro Dissolution Release study 
6.3.6.1 Dissolution conditions 
Medium : 0.7% tween-20 in 0.05 M phosphate buffer, PH 6.5 
Volume : 900ml 
Temperature : 37oC ± 0.5oC 
Apparatus : USP type –II (paddle) 
RPM  : 50 
Time interval : 10, 20, 30, 45 and 60 min. 
Blank, standard and sample preparations of equal volume were separately injected and 
the chromatograms are recorded. The content (%) of candesartan in the portion of 
candesartan tablet was calculated by the formula 
% of labeled amount of candesartan dissolved: 
 
 
 
Where, 
 SA = Peak area response due of candesartan from standard preparation 
 TA =  Peak area response due of candesartan from sample preparation 
 SW = Weight of candesartan working standard (mg) 
 P = Purity of candesartan working standard 
 
 
TA   X    SW    X      5      X     900      X      P     X     100 
SA           200           25      1              100             32 
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7. STABILITY STUDIES 
Dissolution of trial F – 08 tablets were comparable with reference product. So 
tablets of this batch were kept for stability studies. The tablets were tested for average 
weight, thickness, hardness, friability, disintegration, assay, water content and related 
substance at initial, 1 month and 3 months. 
The results of stability studies are shown in Table. After 3 months the physical 
parameters of the tablets were same. Drug content, water content and related substance 
are with inthe limits.  
TABLE:15 STABILITY STUDY DATA OF FORMULATION F – 08 
S.No Parameters 
Conditions 
Initial 250C ± 20C 40 ± 20C & 75 ± 5% RH 
0 Day 3 Months 1 Month 3 Month 
1 
Average Weight 
(mg) 
260.2 ± 0.13 259.9± 0.2 260.4± 0.23 260.6± 0.3 
2 Thickness (cm) 3.53 ± 0.02 3.52 ± 0.04 3.52 ± 0.06 3.50 ± 0.02 
3 Hardness (kg/cm2) 8.12 ± 0.47 8.11± 0.24 8.1± 0.36 7.9± 0.45 
4 Friability (%) 0.06 0.07 0.17 0.19 
5 
Disintegration 
(min) 
11 10 11 9 
6 Assay (%) 99.8 99.9 98.7 98.6 
7 Water content (%) 4.6 4.5 4.3 4.5 
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TABLE:16 DISSOLUTION PROFILE OF FORMULATION F – 08 STABILITY 
STUDY  
S.No    Time(min) 
                                         Conditions 
         Initial  250C ± 20C 40 ± 20C & 75 ± 5% RH 
       0 Day   3 Months  1 Month  3 Months 
1        10        67.4      65.8     66.9    64.3 
2        20       94.5     93.6      94.1    93.1  
3       30       98.9     97.4      98.6    97.6 
4       45      99.7     98.8      99.6    98.8 
5       60     99.9    99.3     99.8    99.6 
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Figure No:22 Dissolution profile for initial and 3 months  stability study of 
formulation F-8 at 250c±20c 
 
 
 
Figure No:23 Dissolution profile for 1 month and 3 months  stability study of 
formulation F-8 at 40 ± 20C & 75 ± 5% RH 
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8. RESULTS AND DISCUSSIONS 
8.1 Preformulation studies 
Preformulation studies like physical characterization, solubility, moisture content, 
flow properties like angle of repose, bulk density, tapped density, compressibility index 
and hausner ratio were performed for drug and the obtained data are presented in the 
Table. 
TABLE:17 PHYSICAL CHARACTERIZATION OF CANDESARTAN 
CILEXETIL 
S.No: Description Result 
1. Appearance White to off-white powder 
2. Odour Characteristic odour. 
3. Solubility 
Freely soluble in Methylene chloride. Slightly 
soluble in methanol, Practically insoluble in 
water. 
4. Water Content 0.07 % 
 
 
TABLE:18 FLOW PROPERTIES OF API 
S.No Flow Properties Result 
1 Bulk density (g/ml) 0.264 
2 Tapped density (g/ml) 0.562 
3 Carr’s index (%) 52.94% 
4 Hausner’s ratio 2.12 
5 Angle of repose 22.8 o 
 
The results of the study showed that physical characterization of Candesartan 
cilexetil (API) complies with the USP specifications and API was found to have poor 
flow property.  
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8.1.3 COMPATIBILITY STUDY 
The compatibility study for Candesartan cilexetil - excipients mixture was carried 
out to quantify the related substance and physical appearance.  
 
No Characteristic change in the color of the mixture was observed and no 
additional degradation of the product was observed. The increase in impurities at the end 
of the accelerated condition is not significant. All the excipients are stable and compatible 
with active ingredient. Hence, it is recommended that the above excipients can be used in 
further formulation development trials. 
 
TABLE:19 COMPATIBILITY STUDY 
EXCEPIENT 
DESCRIPTION 
DRUG:EXCEPIENT(1:1) 
 
550C±20C 
DRUG:EXCEPIENT(1:1) 
 
450C±20C&75±5% RH 
Lactose White to off White Powder White to off White Powder 
PEG 6000 White Flaky Powder White Flaky Powder 
PG Starch White to off White Powder White to off White Powder 
HPC White to off White Powder White to off White Powder 
Ca CMC White to off White Powder White to off White Powder 
Mg.Stearate White to off White Powder White to off White Powder 
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8.2  RESULTS OF FLOW PROPERTIES OF LUBRICATED BLEND 
The evaluation results for flow properties of granules are described in the 
following Table. 
TABLE:20 EVALUATIONS OF GRANULES 
 
S.No Formulations 
Bulk Density 
(g/ml) 
Tapped Density 
(g/ml) 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
1 F-1 0.596 0.785 24.07 1.31 
2 F-2 0.581 0.714 18.60 1.22 
3 F-3 0.654 0.802 18.45 1.22 
4 F-4 0.694 0.834 16.67 1.2 
5 F-5 0.480 0.625 23.07 1.30 
6 F-6 0.519 0.732 29.09 1.443 
7 F-7 0.583 0.745 21.74 1.277 
8 F-8 0.348 0.527 33.96 1.514 
9 F-9 0.510 0.641 20.40 1.25 
10 F-10 0.500 0.735 32 1.470 
 
INFERENCE:  
The formulation trialsF–1, F–5, F–7,F-9 showed “passable” flow propertieswhere as 
trials F-2, F-3, F-4, F-8, showed “fair” flow properties and trials F-6, F–10 showed very 
poor flow properties. 
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8.3 RESULTS OF EVALUATION OF TABLETS 
The evaluation results of in process properties of tablets are described in the following 
Table. 
TABLE:21 EVALUATION OF TABLETS 
 
S.No Formulations 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Disintegration 
(Min) Friability (%) Assay (%) 
1 F-1 3.62 ± 0.099 4.1 ± 0.31 3.16 0.153 96.4 
2 F-2 3.62 ± 0.016 5.1 ± 0.42 3.02 0.106 97.3 
3 F-3 3.46 ± 0.035 6.19 ± 0.22 8.5 0.377 94.1 
4 F-4 3.46 ± 0.024 9.75 ± 0.51 14.55 0.24 98.5 
5 F-5 3.48 ± 0.029 10.44 ± 0.49 11.5 0.17 97.4 
6 F-6 3.47 ± 0.053 5.46 ± 0.32 11.2 0.28 98.3 
7 F-7 3.47 ± 0.052 9.45 ± 0.59 12 0.23 92.4 
8 F-8 3.53 ± 0.022 8.12 ± 0.47 11 0.06 99.8 
9 F-9 3.55 ± 0.019 9.6 ± 0.35 5.5 0.06 98.5 
10 F-10 3.55 ± 0.016 7.1 ± 0.27 2 0.167 98.2 
11 Innovator 3.50 ± 0.04 9.8 ± 0.14 11.17 0.15 98.8 
 
INFERENCE: 
Formulation trials F-1, F-2, F-6 did not achieve required hardness;drug content 
was found to be less in trial F-7, Trials F-8, F-9 achieved required hardness, friability 
and thickness. 
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8.4 IN-VITRO DISSOLUTION RELEASE 
Comparative In-vitro dissolution release profile for reference drug and all 
formulations at 60 minutes is given in the Table. 
 
TABLE:22 PERCENTAGE OF RELEASE 
S.No Time 
% of Drug Release 
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 Innovator 
1 10 65.6 71.5 69.1 28.0 58.9 39.3 36.3 66.9 75.3 80.4 41.2 
2 20 71.8 78.7 89.0 52.6 81.6 69.2 69.7 94.3 83.6 84.4 75.6 
3 30 79.3 83.5 96.6 81.1 93.4 89.4 83.9 98.7 87.4 90.7 90.4 
4 45 86.1 91.4 97.8 91.7 95.1 93.3 91.6 99.3 92.8 92.4 96.7 
5 60 93.4 96.8 98.4 98.8 97.8 96.6 96.5 99.9 98.9 94.9 98.7 
 
We selected F - 8 as the best formulation as it showed total drug release with in 30 
min than all other formulations when compared to the reference product as well as 
showed greater drug release at all the tested time points compared to the innovator 
product. 
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Figure No:24  In-vitro Drug release of formulation F – 1. 
 
 
Figure No:25  In-vitro Drug release of formulation F – 2. 
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Figure No:26 In-vitro Drug release of formulation F – 3. 
 
Figure No:27  In-vitro Drug release of formulation F – 4. 
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Figure No:28  In-vitro Drug release of formulation F – 5 
. 
Figure No:29  In-vitro Drug release of formulation F – 6. 
 
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
C
u
m
u
la
ti
v
e
 %
 D
ru
g
 r
e
le
a
se
Time(min)
F4
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
C
u
m
u
la
ti
v
e
 %
 D
ru
g
 r
e
le
a
se
Time(min)
F6
Results and Discussion 
 
Padmavathi College of Pharmacy and Research Institute 77 
Figure No:30  In-vitro Drug release of formulation F – 7. 
 
 
Figure No:31  In-vitro Drug release of formulation F – 8. 
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Figure No:32  In-vitro Drug release of formulation F – 9. 
 
Figure No:33  In-vitro Drug release of formulation F – 10 
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Figure No:34  In-vitro Drug release of Reference sample. 
 
 
Figure No:35 Comparative In-vitro Drug release of Formulations F – 1, 2, 3,4,5 and 
reference sample. 
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Figure No:36 Comparative In-vitro Drug release of Formulations F – 6,7,8,9,10 and 
reference sample. 
 
 
Figure No:37 Comparative In-vitro Drug release of Formulation F – 8 and reference 
sample. 
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DISCUSSION 
Formulations F– 1 & 2 of Candesartan cilexetil (32mg) was formulated by using 
unmicronized and micronized API. This formulation was done to determine whether 
particle size vary with flow properties or not. The results of the study showed that 
micronized API (F – 2) has good flow properties. Hence micronized API was selected for 
further studies. 
Formulation F – 3In this study candesartan cilexetil was formulated by reducing 
PEG and Ca.CMC concentration. This study was done to match the reference drug in 
terms of appearance, thickness, hardness and in-vitro drug release. The results showed 
that the total drug release was found to be less when compared to the reference product. 
Formulation F – 4 of Candesartan cilexetil was formulated by reducing the 
quantity of PEG and increasing the amount of Klucel. The results showed that the total 
drug release was found to be less when compared to the reference product. 
Formulation F-5 was formulated without PEG. The results of this study showed 
poor flow properties. 
Formulation F-6 of Candesartan cilexetil was formulated by including Povidone 
k-30 as binder. The results of this study showed very poor flow properties. 
Formulation F-7 of Candesartan cilexetil was formulated by incorporating Avicel 
PH 101 and eliminating Corn starch. The results showed passable flow properties and did 
not achieve required assay value.  
Formulation F-8 of Candesartan cilexetil was formulated by incorporating Avicel 
PH 101 and reducing the quantity of Lactose and Starch. The results showed fair flow 
properties and achieved total drug release with in 30min.  
Formulation F-9 was formulated by incorporating Avicel PH 101 and eliminating 
Lactose, PEG. The formulation achieved required drug release but showed passable flow 
properties   
Formulation F-10 was formulated using direct compression method. Spray dried 
lactose was used instead of lactose. The study resulted in poor flow properties.  
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9. SUMMARY AND CONCLUSION 
The    present   study   was   to   develope   and   evaluate   candesartan   cilexetil   
tablets (32 mg). 
 
Based on literature survey and compatibility test excipients like microcrystalline 
cellulose (pH 101), PEG – 6000, pre gelatinized starch, hydroxypropyl cellulose, carboxy 
methyl cellulose, magnesium stearate were used.  In this present study, the tablets were 
prepared by using wet granulation technique. In order to optimize the product, different 
formulations were developed. 
All the formulations were evaluated for physical characteristics, disintegration, in-
vitrodissolution and stability studies.  
Based on the dissolution profile and physical characteristics Formulation F – 08 
was selected as the best formulation for further studies. 
Stability studies were performed for this batch for 1 and 3 months under 
accelerated and long term testing conditions. The product was analyzed for physical 
appearance, hardness, thickness, friability, loss on drying, disintegration, assay and 
related substance at different time intervals. The results obtained were found to be with in 
the specified limits. 
The confirmatory batch is under 6 months accelerated stability condition, based on the 
result, a pilot scale will be executed. 
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